Product Description
Mechanisms of Action: B2 Agonist
Novel Mechanism: Yes
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alkermes
Company Location: DUBLIN 4 L2 00000
Company CEO: Richard F. Pops
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Brain Stem Cancer
Phase 1: Medulloblastoma|Glioma|Brain Stem Cancer|Meningitis, Cryptococcal|Acquired Immunodeficiency Syndrome|HIV Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00005602 |
ADVL0012 | P1 |
Completed |
Glioma|Brain Stem Cancer |
2005-01-01 |
2019-03-21 |
Treatments |
|
NCT00001502 |
96-C-0068 | P1 |
Completed |
Medulloblastoma|Glioma |
None |
2019-03-21 |
||
NCT00002316 |
131A | P1 |
Completed |
Meningitis, Cryptococcal|Acquired Immunodeficiency Syndrome|HIV Infections |
None |
2019-03-21 |
Treatments |
|
NCT00019422 |
CDR0000066169 | P2 |
Completed |
Brain Stem Cancer |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/18/2020 |
PubMed |
Blood-Brain Barrier Disruption in Neuro-Oncology: Strategies, Failures, and Challenges to Overcome. |
|
03/01/2020 |
PubMed |
Cyclooxygenase activity in bradykinin-induced dermal extravasation. A study in mice and humans. |